CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
Exploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …
burdened cancer patients with onerous physical and psychological challenges …
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
E Baulu, C Gardet, N Chuvin, S Depil - Science Advances, 2023 - science.org
T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …
Non-viral precision T cell receptor replacement for personalized cell therapy
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
The future of engineered immune cell therapies
Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …
“living drug” when transferred into patients. Therapies based on engineered immune cells …
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …